Evidence map›Paper›PMID 42629542›Full record

ArticleDrug delivery and translational research2026

Biguanide‑modified ursolic acid as a multifunctional lipid‑mimetic carrier of DOX liposome for synergistic chemotherapy.

Yanzhi Wang, Lei Zhang, Panying Cui, Yanting Fan, Jiaxin Zheng, Hongmin Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yanzhi WangKey Laboratory of Advanced Drug Preparation Technologies, Henan Key Laboratory of Drug Quality Control & Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Ministry of Education of China, Zhengzhou, China. wangyz@zzu.edu.cn.ORCID http://orcid.org/0000-0002-4570-1711
Lei ZhangKey Laboratory of Advanced Drug Preparation Technologies, Henan Key Laboratory of Drug Quality Control & Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Ministry of Education of China, Zhengzhou, China.
Panying CuiKey Laboratory of Advanced Drug Preparation Technologies, Henan Key Laboratory of Drug Quality Control & Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Ministry of Education of China, Zhengzhou, China.
Yanting FanKey Laboratory of Advanced Drug Preparation Technologies, Henan Key Laboratory of Drug Quality Control & Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Ministry of Education of China, Zhengzhou, China.
Jiaxin ZhengKey Laboratory of Advanced Drug Preparation Technologies, Henan Key Laboratory of Drug Quality Control & Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Ministry of Education of China, Zhengzhou, China. zjx1224@163.com.
Hongmin LiuKey Laboratory of Advanced Drug Preparation Technologies, Henan Key Laboratory of Drug Quality Control & Evaluation, School of Pharmaceutical Sciences, Zhengzhou University, Ministry of Education of China, Zhengzhou, China. liuhm@zzu.edu.cn.

Funding

the Key Scientific and Technological Research Project of Henan Province 252102311234the Provincial Key Scientific Research Projects of Colleges and Universities of Henan 25A350008the State Key Laboratory of Cotton Bio-breeding and Integrated Utilization Open Fund CB2025A38
6 · The paper itself

Abstract

Doxorubicin (DOX) therapy is constrained by limited tumor accumulation, inefficient intracellular delivery, and dose-dependent systemic toxicity. Ursolic acid can potentiate DOX activity, but its poor compatibility with liposomal assembly complicates stable co-loading. We synthesized a biguanide-modified UA derivative (UAB) as an amphiphilic lipid-mimetic component and fabricated hyaluronic acid (HA)-modified liposomes co-encapsulating DOX and UAB (HA-DOX@UAB Lips). The optimized formulation showed high encapsulation efficiencies for both agents, a uniform nanoscale size distribution, and pH-dependent DOX release. In BGC-823 gastric cancer cells, HA-DOX@UAB Lips produced the highest intracellular DOX-associated fluorescence, synergistic cytotoxicity, the greatest inhibition of clonogenic growth and wound closure, and the strongest apoptosis-associated response among the tested formulations. In H22 hepatocellular carcinoma-bearing mice used as a non-gastric proof-of-concept model, HA-DOX@UAB Lips produced the greatest tumor suppression without overt short-term organ injury. These findings support UAB as a multifunctional lipid-mimetic component and bioactive partner for DOX co-delivery. Further studies in dedicated gastric cancer models and receptor-specific experiments are required to establish gastric-cancer-specific efficacy and the contribution of CD44 to cellular uptake.

Indexed as

Biguanide‑modified ursolic acidCombination chemotherapyDoxorubicinHyaluronic acidLiposomesSynergistic co-delivery

Identifiers

PMID42629542

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.